The estimated Net Worth of Cameron Gray is at least 473 千$ dollars as of 29 September 2020. Cameron Gray owns over 10,000 units of Cue Biopharma Inc stock worth over 399,725$ and over the last 7 years he sold CUE stock worth over 0$. In addition, he makes 73,256$ as Independent Director at Cue Biopharma Inc.
Sign up
Cameron Gray CUE stock SEC Form 4 insiders trading
Cameron has made over 1 trades of the Cue Biopharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CUE stock worth 151,500$ on 29 September 2020.
The largest trade he's ever made was buying 10,000 units of Cue Biopharma Inc stock on 29 September 2020 worth over 151,500$. On average, Cameron trades about 1,250 units every 0 days since 2017. As of 29 September 2020 he still owns at least 677,500 units of Cue Biopharma Inc stock.
You can see the complete history of Cameron Gray stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cameron Gray biography
Dr. Cameron Gray J.D., Ph.D. serves as Independent Director of the Company. He has been a member of our board of directors since January 2015 and served as our Chief Executive Officer from January 2015 to August 2016. Dr. Gray founded Alcedo Capital in December 2019. He was a Managing Director at MDB Capital Group LLC from September 2013 to November 2019. Dr. Gray served as Chief Executive Officer and a member of the board of directors of Endeavor IP, Inc., an intellectual property services and patent licensing company, from May 2013 through January 2014. He was self-employed from January 2012 through May 2013 and prior to that he was Senior Vice President at ICAP Patent Brokerage, LLC, where he managed its life sciences and Asia Pacific businesses from January 2009 through January 2012. Dr. Gray has a Juris Doctor degree from George Washington University School of Law, a Ph.D. in biophysics from the University of Virginia, and a Bachelor of Arts degree in physics from Princeton University. Dr. Gray’s extensive industry, executive and board experience position him well to serve as a member of our board of directors.
What is the salary of Cameron Gray?
As the Independent Director of Cue Biopharma Inc, the total compensation of Cameron Gray at Cue Biopharma Inc is 73,256$. There are 11 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of 4,559,810$.
How old is Cameron Gray?
Cameron Gray is 49, he's been the Independent Director of Cue Biopharma Inc since 2019. There are 13 older and 6 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
What's Cameron Gray's mailing address?
Cameron's mailing address filed with the SEC is 21 Erie St, Cambridge, MA 02139, USA.
Insiders trading at Cue Biopharma Inc
Over the last 7 years, insiders at Cue Biopharma Inc have traded over 1,426,672$ worth of Cue Biopharma Inc stock and bought 1,194,685 units worth 5,848,356$ . The most active insiders traders include Daniel R Passeri、Aaron G.L. Fletcher、Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of 18,162$. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth 11,040$.
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
What does Cue Biopharma Inc's logo look like?
Complete history of Cameron Gray stock trades at Cue Biopharma Inc
Cue Biopharma Inc executives and stock owners
Cue Biopharma Inc executives and other stock owners filed with the SEC include:
-
Anish Suri,
President, Chief Scientific Officer -
Daniel Passeri,
Chief Executive Officer, Director -
Daniel R. Passeri M.Sc., MSc., J.D.,
CEO & Director -
Colin Sandercock,
Senior Vice President, General Counsel, Secretary -
Dr. Anish Suri Ph.D.,
Pres & Chief Scientific Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Aaron Fletcher,
Independent Director -
Barry Simon,
Independent Director -
Peter Kiener,
Independent Director -
Frederick Driscoll,
Independent Director -
Frank Morich,
Independent Chairman of the Board -
Cameron Gray,
Independent Director -
Tamar Howson,
Director -
Kenneth Pienta,
Chief Medical Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Dr. Kenneth J. Pienta,
Acting Chief Medical Officer -
Dr. Ronald D. Seidel III, Ph.D.,
Co-Founder -
Dr. Matteo Levisetti M.D.,
Sr. VP of Clinical Devel. -
Dr. Ronald D. Seidel III,
Exec. VP and Head of R&D -
Colin G. Sandercock J.D., MSE,
Sr. VP, Gen. Counsel & Sec. -
George B. Zavoico Ph.D.,
VP of Investor Relations & Corp. Devel. -
Dr. Steven C. Almo,
Co-Founder and Chairman of Scientific & Clinical Advisory Board -
Dr. Rodolfo J. Chaparro,
Co-Founder & Sr. Advisor -
Bethany Mancilla,
SVP and Chief Business Officer -
Ronald D. Iii Seidel,
EVP, Head of R&D -
Christopher A Marlett,
Director -
Anthony Digiandomenico,
Director -
Rodolfo Chaparro,
EVP, Head of Immunology -
Steven L Mcknight,
Director -
Patricia Nasshorn,
Chief Business Officer -
Matteo Levisetti,
Chief Medical Officer -
Michael J Fox,
-
Pamela Garzone,
-
Patrick Verheyen,
-
Lucinda Warren,
CHIEF BUSINESS OFFICER